RVNC - Revance Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Revance Therapeutics, Inc.

7555 Gateway Boulevard
Newark, CA 94560
United States

Full Time Employees131

Key Executives

Mr. L. Daniel BrowneCo-Founder, CEO, Pres & Director783.49kN/A55
Mrs. Lauren P. SilvernailChief Financial Officer, Chief Bus. Officer and Sec.651.86kN/A58
Dr. Abhay Joshi Ph.D., M.B.A.Chief Operating Officer800.88kN/A54
Mr. Justin FordHead of People & VP of HRN/AN/AN/A
Mr. Todd Erik ZavodnickChief Commercial Officer and Pres of Aesthetics & TherapeuticsN/AN/A45
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Corporate Governance

Revance Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.